The largest blog for reading the latest medical research on all disease, the prevention and its treatment . Pulled from variety of sources

Saturday, November 26, 2016

Bad news for Alzheimer’s disease research according to : "startsat60"

This content may collect you by Lucy William

We will quote to you the news of the best health sites Like : "startsat60" and the most famous medical experts : View Profile


daily : 2016-11-26 & on time : 4:51


follow all the new news about Disease

as declared in





Bad news for Alzheimer's disease research


Bad news for Alzheimer's disease research
image uploaded by "startsat60" site
Portrait of an old lonely man looking out the windowA drug trial that many had hoped would treat Alzheimer's disease has failed in its major clinical trial, a heartbreaking setback for those suffering or caring for someone suffering the disease.Pharmaceutical company Eli Lilly announced they would not be moving forward with regulatory approval to market the drug solanezumab for mild dementia because it didn't slow down the cognitive decline in patients.The results of the trial had been greatly anticipated after the company released promising results in 2015.Had the trial been successful it would have shown that beta amyloid, clumps of a 'toxic' protein that builds up in the brains of Alzheimer's patients, contribute to the causes of the disease.
about the details read more from here


Eli Lilly's Alzheimer's disease drug fails in final-stage trial


Eli Lilly's Alzheimer's disease drug fails in final-stage trial
image uploaded by "post-gazette" site
Eli Lilly & Co.'s experimental Alzheimer's treatment failed to slow the progression of the neurodegenerative disease, yet another setback to drugmakers and researchers who continue to seek a way to treat one of the most feared ailments in the world.More than 2,100 people with mild Alzheimer's who were treated with solanezumab didn't show a meaningful slowing of cognitive decline compared with those who got a placebo, Lilly said in a statement Wednesday.The drugmaker said it hasn't decided what next steps, if any, to take with the medicine.The results of the trial "were not what we had hoped for and we are disappointed for the millions of people waiting for a potential disease-modifying treatment," said John Lechleiter, Lilly's outgoing CEO.
about the details read more from here


Failed Alzheimer's trial does not kill leading theory of disease


Failed Alzheimer's trial does not kill leading theory of disease
image uploaded by "nature" site
Jessica Wilson/Science Photo LibraryA drug that was seen as a major test of the leading theory behind Alzheimer's disease has failed in a large trial of people with mild dementia.Critics of the 'amyloid hypothesis', which posits that the disease is triggered by a build-up of amyloid protein in the brain, have seized on the results as evidence of its weakness.But the jury is still out on whether the theory will eventually yield a treatment.Proponents of the theory note that the particular way in which solanezumab, the drug involved in the trial, works could have led to the failure, rather than a flaw in the hypothesis itself.
about the details read more from here


To follow all the new news about Disease !!! All you need to know about all kinds of diseases

No comments:

Post a Comment